Psychemedics (PMDI) AI Stock Analysis

Psychemedics

(Other OTC:PMDI)

Select Model

Rating:42Neutral

Action:N/A

Date:12/31/24

Psychemedics' stock is under pressure primarily due to weak financial performance and negative investor sentiment post-earnings. The lack of profitability, deteriorating price trends, and absence of compelling valuation metrics contribute to a low overall score. Improvements in financial health and positive future guidance are essential for a better outlook.

Positive Factors

Patented TechnologyPsychemedics' patented hair testing technology provides a competitive advantage by offering a longer detection window, enhancing its market position in drug testing.

Negative Factors

Declining RevenuesPersistent revenue decline suggests challenges in market demand or competition, which could impact long-term growth and profitability.

Psychemedics (PMDI) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $15.24M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): ―
Beta (1Y): 0.46
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 116
Sector: Healthcare
Sector Strength: 51
Industry: Medical Diagnostics & Screening

Psychemedics Business Overview & Revenue Model

Company Description

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, schoo...

How the Company Makes Money

Psychemedics Corporation generates revenue primarily through the provision of drug testing services. The company charges its clients, which include corporations, government agencies, and educational institutions, for conducting hair analysis tests th...

Psychemedics Technical Analysis

Technical Analysis SentimentPositive

Last Price2.49

Price Trends

50DMA2.49Positive

100DMA2.46Positive

200DMA2.17Positive

Market Momentum

MACD0.00Positive

RSI79.42Negative

STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMDI, the sentiment is Positive. The current price of 2.49 is below the 20-day moving average (MA) of 2.49, above the 50-day MA of 2.49, and above the 200-day MA of 2.17, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 79.42 is Negative, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMDI.

Psychemedics Risk Analysis

Psychemedics disclosed 26 risk factors in its most recent earnings report. Psychemedics reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.<a></a> Item 1A. of our Annual Report on Form 10-K for the year ended December 31,Q3, 2024

Psychemedics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PMDI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TXMD	65Neutral	$20.83M	-95.74	-0.80%	―	27.78%	52.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRKR	47Neutral	$16.34M	-2.04	-56.96%	―	-56.64%	64.88%
IMNN	46Neutral	$5.11M	-0.20	-314.89%	―	―	71.67%
BIAF	43Neutral	$3.73M	-0.02	-257.27%	―	-23.17%	67.18%
PMDI	42Neutral	$15.24M	―	―	―	―	―

* Healthcare Sector Average

Performance Comparison

PMDI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PMDI	Psychemedics Corporation	2.49	0.37	17.45%
IMNN	Imunon, Inc.	0.91	-3.48	-79.27%
TXMD	Therapeuticsmd Inc	1.80	0.65	56.52%
MRKR	Marker Therapeutics	0.98	0.02	2.19%
BIAF	bioAffinity Technologies, Inc.	2.91	-31.59	-91.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Dec 31, 2024

Psychemedics AI Stock Analysis